Pricing Log in Create free account

EyePoint, Inc. (EYPT) vs INmune Bio, Inc. (INMB)

EyePoint, Inc. and INmune Bio, Inc. are both Biotechnology companies. EyePoint, Inc. and INmune Bio, Inc. are of similar size ($32.6M and $30.7M). INmune Bio, Inc. grew revenue faster over the last twelve months: −51.6% against −94.6%. INmune Bio, Inc. has the higher net margin (0.00% vs −10,998.7%) and the lower return on invested capital (−646.9% vs 0.00%). Across the 17 metrics below, INmune Bio, Inc. leads on 12 and EyePoint, Inc. on 5.

Valuation

Metric EYPT INMB Biotechnology median
P/E n/m n/m 10.60
P/S 11.17 221.67 9.40
P/B 0.19 1.47 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.36 n/m 0.66
EV/Sales (41.12) 121.37 9.02
Earnings yield (1,038.89%) (59.82%) (32.88%)
Free cash flow yield (870.23%) (54.91%) (23.13%)

Profitability

Metric EYPT INMB Biotechnology median
Gross margin 41.75% 100.00% 68.51%
Operating margin (11,369.30%) 0.00% 0.00%
Net margin (10,998.67%) 0.00% 0.00%
Free cash flow margin (9,724.68%) 0.00% 0.00%
Return on equity (148.70%) (74.82%) (51.96%)
Return on assets (115.86%) (57.08%) (46.06%)
Return on invested capital 0.00% (646.94%) 0.00%

Growth

Metric EYPT INMB Biotechnology median
Revenue growth (TTM) (94.63%) (51.61%) 6.76%
EPS growth (last fiscal year) (36.64%) 11.85% 29.88%
Revenue growth, 5-year CAGR (1.85%) 35.37% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric EYPT INMB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 4.50 4.04 4.97
Net debt to EBITDA 1.24 0.52 1.01

Dividend

Metric EYPT INMB Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric EYPT INMB Biotechnology median
Market cap 30.68m 32.61m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack